Table 2.
Total combined score (TCS), daily symptom score (DSS), and daily medication score (DMS) in the Canadian subpopulation during the peak and entire ragweed pollen season (FAS population)
| Peak ragweed pollen season | Entire ragweed pollen season | |||
|---|---|---|---|---|
| Scale | Ragweed SLIT-tablet | Placebo | Ragweed SLIT-tablet | Placebo |
| TCS, LS mean | 2.32 | 3.91 | 2.36 | 3.73 |
| n | 99 | 124 | 99 | 124 |
| Difference vs placebo (95% CI) | − 1.59 (− 2.54, − 0.65) | – | − 1.36 (− 2.21, − 0.51) | – |
| Reduction vs placebo, % (95% CI) | − 40.8 (− 54.5, − 20.2) | – | − 36.6 (− 50.2, − 16.5) | – |
| P value | 0.001 | – | 0.002 | – |
| DSS, LS mean | 2.12 | 3.06 | 2.12 | 2.89 |
| n | 99 | 125 | 99 | 125 |
| Difference vs placebo (95% CI) | − 0.94 (− 1.65, − 0.22) | – | − 0.77 (− 1.43, − 0.11) | – |
| Reduction vs placebo, % (95% CI) | − 30.6 (− 45.2, − 7.7) | – | − 26.6 (− 41.6, − 3.9) | – |
| P value | 0.010 | – | 0.022 | – |
| DMS, LS mean | 0.20 | 0.86 | 0.24 | 0.84 |
| n | 99 | 124 | 99 | 124 |
| Difference vs placebo (95% CI) | − 0.66 (− 1.10, − 0.23) | – | − 0.59 (− 0.95, − 0.24) | – |
| Reduction vs placebo, % (95% CI) | − 77.2 (− 97.5, − 44.2) | – | − 70.8 (− 88.1, − 43.5) | – |
| P value | 0.003 | – | 0.001 | – |
FAS full analysis set, LS least square, SLIT sublingual immunotherapy